The dipeptidyl peptidase 4 (DPP4) inhibitor vildagliptin prevented MASLD-HCC in mouse models challenged with DEN and HFD by reversing HFD-induced CCL-2 production and angiogenesis, suggesting that the DPP4/CCL2/angiogenesis axis plays a key role in inhibiting MASLD-HCC. This evidence concerns the gene CCL2 and hepatocellular carcinoma.